HEALTHNPR NEWS
Key FDA committee unanimously recommends its first vaccine since 2023
A key FDA committee unanimously recommended Moderna's new mRNA influenza vaccine for adults aged 50 and over. All nine committee members voted in favor of the recommendation.
Related Signal
Adjacent reporting
- Key FDA committee unanimously recommends its first vaccine since 2023
- FDA panel recommends mRNA flu vaccine for older adults
- FDA panel backs first-of-its-kind flu vaccine using mRNA technology
- FDA panel recommends Moderna’s mRNA flu shot for older adults
- STAT+: FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy